1. Patients' and oncologists' preferences for second-line maintenance PARP inhibitor therapy in epithelial ovarian cancer.
- Author
-
Stone RL, Cambron-Mellott MJ, Beusterien K, Maculaitis MC, Ritz S, Mulvihill E, Monberg M, Szamreta EA, Amin S, and McLaurin K
- Subjects
- Adult, Aged, Cost-Benefit Analysis, Decision Making, Drug-Related Side Effects and Adverse Reactions therapy, Female, Humans, Maintenance Chemotherapy, Middle Aged, Progression-Free Survival, United States epidemiology, Young Adult, Carcinoma, Ovarian Epithelial drug therapy, Oncologists statistics & numerical data, Ovarian Neoplasms drug therapy, Patient Preference statistics & numerical data, Poly(ADP-ribose) Polymerase Inhibitors therapeutic use
- Abstract
Aim: To understand the preferences of US patients and oncologists for PARP inhibitors as second-line maintenance (2LM) for epithelial ovarian cancer. Methods: A discrete choice experiment was conducted to assess the preferences of treatment attributes. Results: The most valued attributes were risk of grade 3/4 adverse events (AEs; patients, n = 204) and progression-free survival (PFS; oncologists, n = 151). To accept a 37% increased risk of grade 3/4 AEs, PFS would need to increase by 27.9 months (patients) and 6.3 months (oncologists). The least valued attributes were dosing form/frequency (patients) and grade 3/4 anemia risk (oncologists). Conclusion: Patients' and oncologists' willingness to make benefit-risk trade-offs in the 2LM setting suggests that the PFS gains observed in selected studies of poly (ADP-ribose) polymerase inhibitors in BRCA-mutated disease are worth the toxicity risk.
- Published
- 2022
- Full Text
- View/download PDF